Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe have developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of our platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. We have miniaturized traditional chemical DNA synthesis reactions to write over 1,000,000 pieces of DNA (oligonucleotides) up to 500 bases through direct synthesis on each silicon chip, approximately the size of a large mobile phone, reducing by 99.8% the amount of chemicals we estimate would be used per gene as compared to plate-based synthesis.
In the company’s own words · 10-K filed Nov 17, 2025 · SEC EDGAR
Business segments
Q1 2026 · $110.7MThe company’s own SEC segment disclosure.
- Ngs Tools$57.4M52%
- Antibody Discovery$53.3M48%
Twist Bioscience Corporation (TWST) reported revenue of $118M in Q3 2026 (quarter ended June 30, 2026), up 23% from the same quarter a year earlier. That came with a gross margin of 53% and net loss of $35M. For the full year FY2025, revenue was $377M (+20% year on year) and net income −$78M. Its largest product in 2026-Q1 was Ngs Tools at $57M, 52% of the disclosed total, just ahead of Antibody Discovery at 48%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.
Diagnostics & Research
Ranks #4 of 29 by Smart Score